by The global gene and cell therapies targeting CNS disorders market is a rapidly evolving space comprising cell-based therapies and gene-based therapies which are being explored for treatment of various central nervous system (CNS) disorders such as neurological diseases, neurodegenerative disorders, and others. Gene therapies involve alteration of genetic material of cells for treatment of a disease by delivery of therapeutic gene, while cell therapies involve transplantation of stem/progenitor cells for repair or replacement of damaged cells. The cell-based therapies are aimed at repairing damage done due to various CNS disorders by replacing or regenerating damaged cells in the brain or spinal cord. Gene therapies are focused on correcting the underlying genetic defects responsible for causing neurological diseases and disorders.
The global gene and cell therapies targeting CNS disorders market is estimated to be valued at US$ 9.45 Mn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the gene and cell therapies targeting CNS disorders are Byucksan, Great Lakes Textiles, ISOVER (Saint Gobain), mJohns Manville, Knauf Insulation, National Industrial Co., NTN OOD, Owens Corning, PGF Insulation, Rockwool International AS, Kingspan Group, and Rosewool Insulation Refractory Co. Ltd.
The key opportunities in the market include large patient pool for CNS disorders, increasing R&D funding for gene and cell therapies, and development of novel treatment approaches for neurodegenerative diseases. Advancements in gene therapy technologies such as adeno-associated virus (AAV) gene delivery systems, mRNA therapeutics, CAR T-cell therapies have boosted research in gene and cell therapies targeting CNS disorders.
Market Drivers
The major market driver is the large unmet clinical need for effective treatment of CNS disorders. Currently available treatment options for various neurological and neurodegenerative disorders only manage symptoms and do not provide cure. Gene And Cell Therapies Targeting CNS Disorders Market Demand l for targeted disease-modifying therapies with long-lasting therapeutic effects. Rising prevalence of conditions such as Alzheimer’s disease, Parkinson’s disease, motor neuron diseases, and others are also fueling demand for advanced treatment paradigms. Increasing investments from industry players and government funding for research and clinical trials will propel market growth over the forecast period.
Current challenges in Gene and Cell Therapies Targeting CNS Disorders Market:
The Gene And Cell Therapies Targeting CNS Disorders Market is still in its nascent stages with various technical and regulatory challenges. Developing safe and effective gene and cell therapies is complex with risks of adverse effects. Demonstrating therapeutic efficacy and obtaining regulatory approvals requires extensive research and clinical trials. High costs associated with R&D and productions pose challenges for commercialization. Lack of standardization and infrastructure for manufacturing and delivery pose as bottlenecks. Educating patients, caregivers, healthcare staff and payers about new treatment modalities also requires efforts. Sustaining product efficiencies and safety over long term with a single administration also needs to be established. Overall, overcoming these challenges would be critical for realizing the true potential of these novel therapies.
SWOT Analysis
Strengths: Emerging as a promising avenue to target previously untreatable disorders. Potential to provide long lasting effects with a single administration.
Weaknesses: High costs of development and production. Complex manufacturing and delivery mechanisms. Risks of adverse effects need to be addressed.
Opportunities: Significant unmet medical need. Growing patient acceptance for novel options. Potential for numerous applications across different disorders.
Threats: Lengthy approval process. Strong competition from conventional therapies. Need for extensive clinical validation and long term safety data. Regulatory uncertainties pose risks.
In terms of geographical concentration of market value, North America currently dominates the Gene and Cell Therapies Targeting CNS Disorders Market. Presence of major players, rising healthcare investments, availability ofadvanced healthcare facilities and growing patient awareness drive the North American market. U.S. accounts for the largest share.
Europe is also among the major markets for gene and cell therapies targeting CNS disorders. Increasing research collaborations, healthcare reforms and favorable regulatory environment support growth in Europe. Asia Pacific region is emerging as the fastest growing market owing to rapidly developing healthcare infrastructure, rising medical tourism, growing investments by market players and increasing focus on neurological disorders. China and India are expected to provide significant opportunities over the forecast period.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it.
